Beverly “Sunshine” Pegues dons her helmet, adjusts her gloves, swings her leg over her saddle and rides into the early dawn sunshine in Seattle. Birdsong punctuates the hushed morning sounds. Her bicycle tires crunch along the sandy road. Riding strong and confident, she picks up speed. She is on the road, training for Obliteride, an annual 25-to-100-mile fundraiser for Fred Hutchinson Cancer Research Center (Fred Hutch).
He rides with purpose. Along the rural stretches of Snoqualmie Valley, David Dunnington rides for hours and miles in his steadfast determination to make inroads against cancer. “When I'm riding my bike, I’m thinking—I’m back. I think about what it feels like — the wind in my face. I feel how lucky I am to have gotten to this place. I just feel very grateful.”
When Seattle Mayor Jenny Durkan was newly diagnosed with melanoma in January, her surgical oncologist acknowledged the delicate and difficult nature of having cancer and being the public face of the Emerald City.
Marc Mutz sits comfortably in the patient lounge of Seattle Cancer Care Alliance’s (SCCA) Clinical Trials Unit (CTU), receiving his 75th dose of nivolumab. One of the newest immunotherapy drugs available, it has helped keep his metastatic renal cell cancer in check for three years.